梅特福林用于治疗青光眼的治疗方法
Qëndresë Daka1,2, Burim Neziri1, Ewald Lindner3
1Department of Pathophysiology, Medical Faculty, University of Prishtina, Prishtinë, Kosovo.
Journal of glaucoma
|March 27, 2024
概括
梅特福明通过调节神经保护通路显示出对眼治疗的潜力,但需要严格的临床试验来确认其安全性和有效性. 进一步的研究是必要的,以探索其治疗效益.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 玻璃眼是导致不可逆转失明的主要原因.
- 目前的治疗方法旨在降低眼内压力,但不能完全预防视力丧失.
- 糖尿病药物梅特福明已经显示出潜在的神经保护性质.
研究的目的:
- 为了评估甲胺在青光眼中的潜在益处.
- 调查甲福明对青光眼风险因素的影响背后的机制.
- 促进开发新的青光眼治疗策略.
主要方法:
- 在电子数据库 (PubMed,EMBASE,ClinicalTrials.gov) 中进行系统搜索.
- 包括评估甲胺对青光眼风险因素和机制的影响的研究.
- 对神经保护通路的实验数据的分析.
主要成果:
- 没有特定的临床试验专门研究甲福林治疗青光眼.
- 实验研究表明,甲福明可以调节与眼神经保护相关的途径.
- 梅特福林能够影响像AMPK这样的途径并减少氧化应激的能力被注意到.
结论:
- 根据实验数据,甲胺对玻璃眼的治疗特性具有潜在的治疗特性.
- 严格的临床试验至关重要,以确定甲福林在青光眼患者的安全性和有效性.
- 需要进行进一步的研究,才能充分利用甲胺在综合性玻璃眼治疗策略中的治疗潜力.
相关概念视频
Open Angle Glaucoma: Treatment
440
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
440
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Angle Closure Glaucoma: Treatment
485
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
485
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154


